

Rahul Aggarwal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/958773/publications.pdf>

Version: 2024-02-01

66
papers

3,572
citations

236925

25
h-index

149698

56
g-index

67
all docs

67
docs citations

67
times ranked

5706
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2492-2503.	1.6	477
2	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. <i>Cell</i> , 2018, 174, 758-769.e9.	28.9	459
3	Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	288
4	Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP Inhibitors. <i>Cancer Discovery</i> , 2017, 7, 999-1005.	9.4	223
5	Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. <i>European Urology</i> , 2017, 72, 34-42.	1.9	179
6	⁶⁸ Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. <i>Journal of Nuclear Medicine</i> , 2017, 58, 81-84.	5.0	166
7	Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical Outcomes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 719-726.	4.9	141
8	Hyperpolarized 1-[¹³ C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Androgen Ablation Therapy in Prostate Cancer. <i>European Urology</i> , 2017, 72, 1028-1029.	1.9	127
9	Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 76, 562-571.	1.9	104
10	Investigation of analysis methods for hyperpolarized ¹³ C-pyruvate metabolic MRI in prostate cancer patients. <i>NMR in Biomedicine</i> , 2018, 31, e3997.	2.8	77
11	Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. <i>European Urology Oncology</i> , 2018, 1, 78-82.	5.4	74
12	Hyperpolarized ¹³ C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 269-276.	3.9	68
13	MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 531-538.	3.9	66
14	Translation of Carbon-13 EPI for hyperpolarized MR molecular imaging of prostate and brain cancer patients. <i>Magnetic Resonance in Medicine</i> , 2019, 81, 2702-2709.	3.0	65
15	Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. , 2017, 5, 75.		52
16	The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. <i>Nature Communications</i> , 2021, 12, 7349.	12.8	51
17	Technique development of 3D dynamic CS-EPI for hyperpolarized ¹³ C pyruvate MR molecular imaging of human prostate cancer. <i>Magnetic Resonance in Medicine</i> , 2018, 80, 2062-2072.	3.0	47
18	Accelerating precision medicine in metastatic prostate cancer. <i>Nature Cancer</i> , 2020, 1, 1041-1053.	13.2	45

#	ARTICLE	IF	CITATIONS
19	Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight, 2018, 3, .	5.0	43
20	Cell-free DNA concentration and fragment size as a biomarker for prostate cancer. Scientific Reports, 2021, 11, 5040.	3.3	40
21	Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 910-916.	5.0	35
22	Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. Cancer, 2020, 126, 3972-3981.	4.1	34
23	A Feasibility Study Showing [68Ga]Citrate PET Detects Prostate Cancer. Molecular Imaging and Biology, 2016, 18, 946-951.	2.6	33
24	Response to Subsequent Docetaxel in a Patient Cohort With Metastatic Castration-Resistant Prostate Cancer After Abiraterone Acetate Treatment. Clinical Genitourinary Cancer, 2014, 12, e167-e172.	1.9	32
25	CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield. Journal of Vascular and Interventional Radiology, 2017, 28, 1073-1081.e1.	0.5	30
26	The Mechanism of Action of Estrogen in Castration-Resistant Prostate Cancer: Clues From Hormone Levels. Clinical Genitourinary Cancer, 2009, 7, E71-E76.	1.9	28
27	Castration-Resistant Prostate Cancer: Targeted Therapies and Individualized Treatment. Oncologist, 2011, 16, 264-275.	3.7	27
28	Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Molecular Cancer Research, 2017, 15, 1221-1229.	3.4	27
29	Coil combination methods for multi-channel hyperpolarized 13C imaging data from human studies. Journal of Magnetic Resonance, 2019, 301, 73-79.	2.1	27
30	A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. Npj Precision Oncology, 2021, 5, 74.	5.4	27
31	A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone-and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer. Oncologist, 2018, 23, 656-e64.	3.7	25
32	Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 83-93.	1.6	24
33	Clinical translation of hyperpolarized ¹³ C pyruvate and urea MRI for simultaneous metabolic and perfusion imaging. Magnetic Resonance in Medicine, 2022, 87, 138-149.	3.0	23
34	Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer. Oncotarget, 2017, 8, 71447-71455.	1.8	23
35	Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. , 2021, 9, e002254.		21
36	Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Research, 2017, 19, 107.	5.0	19

#	ARTICLE	IF	CITATIONS
37	Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e92-e96.	1.9	19
38	Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093608.	3.2	19
39	The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer. <i>Cancer</i> , 2013, 119, 3636-3643.	4.1	17
40	Differential Activity of PARP Inhibitors in BRCA1 Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1200-1220.	3.0	17
41	Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Immune Checkpoint Inhibitor Therapy in Prostate Cancer. <i>European Urology</i> , 2022, 81, 219-221.	1.9	17
42	Quantitative and Qualitative Improvement of Low-Count [68Ga]Citrate and [90Y]Microspheres PET Image Reconstructions Using Block Sequential Regularized Expectation Maximization Algorithm. <i>Molecular Imaging and Biology</i> , 2020, 22, 208-216.	2.6	16
43	Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 81-87.	3.9	14
44	Resistance to Androgen Deprivation Leads to Altered Metabolism in Human and Murine Prostate Cancer Cell and Tumor Models. <i>Metabolites</i> , 2021, 11, 139.	2.9	13
45	Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team. <i>European Urology Focus</i> , 2016, 2, 469-471.	3.1	12
46	CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease. <i>Clinical Cancer Research</i> , 2022, 28, 3066-3075.	7.0	10
47	Prostate-specific membrane antigen (PSMA)-based imaging in localized and advanced prostate cancer: a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 3130-3143.	1.4	9
48	Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 359-365.	2.3	8
49	Large remodeling of the Myc-induced cell surface proteome in B cells and prostate cells creates new opportunities for immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	8
50	Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3979-3989.	7.0	8
51	A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 149.e7-149.e13.	1.6	7
52	Approaches to minimize castration in the treatment of advanced prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 368-374.	1.6	6
53	A Complete Metabolic Response of Metastatic Castration-resistant Neuroendocrine Carcinoma of the Prostate After Treatment with RRx-001 and Reintroduced Platinum Doublets. <i>European Urology</i> , 2018, 73, 306-307.	1.9	6
54	Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing. <i>JCO Precision Oncology</i> , 2021, 5, 710-725.	3.0	6

#	ARTICLE	IF	CITATIONS
55	Specialized computational methods for denoising, B 1 correction, and kinetic modeling in hyperpolarized ¹³ C MR EPSI studies of liver tumors. <i>Magnetic Resonance in Medicine</i> , 2021, 86, 2402-2411.	3.0	6
56	Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers. <i>European Urology</i> , 2018, 73, 845-846.	1.9	4
57	The changing role of imaging in clinical care. <i>Nature Reviews Urology</i> , 2014, 11, 75-77.	3.8	3
58	A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 730.e9-730.e15.	1.6	2
59	In Vivo Profiling with ¹⁸ F-YJH08 Reveals Diverse Tissue Patterns of Antagonist/Glucocorticoid Receptor Interactions. <i>Molecular Pharmaceutics</i> , 2022, 19, 704-709.	4.6	2
60	Moving toward a precision medicine approach in metastatic castration-resistant prostate cancer. <i>Lancet Oncology</i> , The, 2017, 18, 1436-1437.	10.7	1
61	Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer. <i>JCO Oncology Practice</i> , 2021, , OP2100480.	2.9	1
62	A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. <i>Cancer Research Communications</i> , 2022, 2, 570-576.	1.7	1
63	Prednisone Use in Conjunction with Abiraterone Acetate: Is Patient Safety a Concern with Long-term Steroid Exposure?. <i>European Urology</i> , 2016, 70, 445-446.	1.9	0
64	Defining the Prognostic and Predictive Impact of Germline DNA Repair Mutations in Patients with Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2018, 73, 694-695.	1.9	0
65	Reply to A. Dalla Volta et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 351-352.	1.6	0
66	Mobile Clinical Trial Matching Technology in Medical Oncology Clinic: A Pilot Feasibility Study. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100182.	2.1	0